Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

SGLT2 inhibitors:

Slowing of chronic kidney disease progression in

type 2 diabetes

Please sign in below:

Your data is being collected by OmniaMed Communications on behalf of Napp Pharmaceuticals solely for the purpose of processing your attendance. Your details will not be shared with any parties other than OmniaMed Communications and Napp Pharmaceuticals Limited.

28 January 2021 at 13:00 and 19:00

This webcast begins in

Days
Hours
Minutes
Seconds

This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. The peer-reviewed publication discussed in this webcast was independently developed by the Improving Diabetes Steering Committee and the Committee remains independent from Napp in the delivery of their commentary on this peer-reviewed publication within this promotional webcast. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed has provided editorial, marketing and logistical support.

Adverse events should be reported.
Reporting forms and information can be found at yellowcard.mhra.gov.uk
Adverse events should also be reported to Napp Pharmaceuticals at drugsafetyuk@napp.co.uk

Date of preparation: January 2021 UK-INV-2000120

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.